$MKGI Announces Agreement With #TriseptSolutions

$ISCO Announces #Q2 #Results

CARLSBAD, Calif., Aug. 16, 2016  — International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and six months ended June 30, 2016.

“We are pleased with the progress of the Company in the second quarter. We continue to generate revenue to finance our research and development activities on the therapeutics side of our business. We are particularly proud to have moved our Parkinson’s Disease program into a Phase I clinical trial in Australia, an important milestone in the Company’s development. We are looking forward to reporting on our progress to you in that as well as other programs that the Company is working on,” said Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO.

Second Quarter 2016 Financial Highlights

• Consolidated revenue for the second quarter of 2016 was 1.9 million, reflecting an increase of 6% compared to the consolidated revenue of $1.8 million for the second quarter of 2015.
• Gross profit margin for the Company’s revenue-generating subsidiaries for the second quarter of 2016 was $1.4 million, or 74%, compared to gross profit margin of $1.3 million, or 72%, for the second quarter of 2015.
• Consolidated loss from operations for the second quarter of 2016 was $1.2 million, compared to consolidated loss from operations of $937,000 for the second quarter of 2015.

Year-to-Date Financial Highlights

• Consolidated revenue for the six months ended June 30, 2016 was 3.5 million, reflecting an increase of 3% compared to the consolidated revenue of $3.4 million for the six months ended June 30, 2015.
• Gross profit margin for the Company’s revenue-generating subsidiaries for the six months ended June 30, 2016 was $2.6 million, or 75%, compared to gross profit margin of $2.5 million, or 73%, for the six months ended June 30, 2015.
• Consolidated loss from operations for the six months ended June 30, of 2016 was $2.4 million, compared to consolidated loss from operations of $2.9 million for the six months ended June 30, 2015.

Recent Corporate Highlights

• The first patient in the Company’s Phase I clinical trial has undergone a successful intracranial transplant of ISC-hpNSC as a treatment under investigation for Parkinson’s Disease (PD). The operation took place at the Royal Melbourne Hospital in Australia.
• Published the results of a 12-month preclinical non-human primate study. The data demonstrates the safety and efficacy of the Company’s proprietary ISC-hpNSC.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.  ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).  hpSCs avoid ethical issues associated with the use or destruction of viable human embryos.  ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, expected clinical studies (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation
Russell Kern, PhD
Executive Vice President

Phone: 760-940-6383
Email: ir@intlstemcell.com

Media:

Alex Fudukidis
Phone: (646) 942-5632
Email: alex.fudukidis@russopartnersllc.com

Tony Russo, Ph.D.
Phone: (212) 845-4251
Email: tony.russo@russopartnersllc.com

$EVLV Most Popular #Watch Brand Launches New #Disney $DIS Collection

MINNEAPOLIS, Aug. 15, 2016  — Evine Live Inc. (NASDAQ:EVLV), a shopping destination and curator of video content across all screens big and small (evine.com), announced today that on August 20^th it will debut a new Disney-themed watch collection from Invicta. Evine will be the first to launch select timepieces from the top watch manufacturer’s exciting new collection.

“For the past 15 years, Invicta has consistently delivered superbly-crafted product that keeps our watch customers excited, engaged and wanting more. With this launch, we expect to appeal to our current Invicta customer base while also attracting a whole new audience of Disney fans to the brand… that’s what makes this launch so special,” said Michael Henry, Chief Merchandising Officer at Evine.

Throughout the premiere, Evine will present a number of Disney watch designs on-air, online and via its mobile apps. In addition to classic Mickey Mouse designs, the launch will also feature Invicta’s most popular collections, including the Pro Diver, Subaqua Noma I, Corduba, Angel, Bone Collector and Speedway collections.

“Because of Invicta’s unique approach to design and engineering, the new Disney collection articulates renderings of favorite Disney characters in an exciting, new way. The combination and result of this vision creates an exceptional opportunity for Invicta collectors,” said Eyal Lalo, CEO of Invicta Watch Group. “It is with great enthusiasm that we look forward to sharing this collection with the Evine viewers.”

The Disney collection from Invicta is a fusion of Disney-inspired elements and Invicta’s most iconic styles. Each timepiece embodies Disney’s classic charm with details such as Mickey Mouse hour markers, mother of pearl Mickey Mouse dials and Disney case backs. Styles are available for both men and women, and shoppers will appreciate a variety of price points, movements and designs. Every timepiece sold on Evine will come packaged in a custom, three-slot Mickey Mouse dive case.

The Disney collection from Invicta debuts live on Evine on August 20^th at 10PM ET, with re-broadcasts on August 21^st at 2AM and 7AM ET.

Viewers are invited to watch the premiere via cable and satellite, mobile apps and live streaming online at www.evine.com. Evine airs on DIRECTV channels 73 and 316, DISH Network channels 134 and 228 and the nation’s top cable providers. Find Evine in your area: bit.ly/1CNa450.

To shop the Disney collection from Invicta, visit www.evine.com/invicta. For more information on Evine, please visit www.evine.com.

About Evine Live Inc.
Evine Live Inc. (NASDAQ:EVLV) operates Evine, a digital commerce company that offers a compelling mix of proprietary and name brands directly to consumers in an engaging and informative shopping experience via television, online and on mobile. Evine reaches approximately 88 million cable and satellite television homes 24 hours a day with entertaining content in a comprehensive digital shopping experience.

About Invicta Watch Group
Led by innovation and nurtured with the consistency of quality and brand personality, the forward thinking energy of The Invicta Watch Group continues its brazen journey. The long held belief that supremely crafted timepieces can be offered for modest sums is the founding principle of Invicta and that ideology still resides at the core of all Invicta creations. In setting a premise of exceptional standards, Invicta maintains their objective by successfully satisfying consumers and collectors alike at any price point.

Please visit www.evine.com/ir for more investor information.

Contacts:

Media:
Carl Schroeder
Evine
press@evine.com
(952) 943-6574

Amanda Zerbib
ALISON BROD PUBLIC RELATIONS
amandaz@alisonbrodpr.com
(212) 230-1800

Gany Lalo
Invicta Watch Group
glalo@invictawatch.com
(954) 921 - 2444

Investors:
Jason Iannazzo
EVINE Live Inc.
jiannazzo@evine.com
(952) 943-6126

$RPRX Six Month Interim #Results, #Enclomiphene #Obesity #Study

Six month interim assessment of testosterone (T) levels shows statistically and clinically significant increases in total T (p = 0.0017) and free T (p = 0.0020) superior to placebo

Diet and exercise alone increased mean total T (263.9 ng/dL to 368.2 ng/dL, p = 0.0055) and mean free T (55.6 pg/mL to 57.1 pg/mL, p = 0.0802)

Enclomiphene treatment combined with diet and exercise increased mean total T (277.3 ng/dL to 780.9 ng/dL, p < 0.0001) and free T (56.3 pg/mL to 140.1 pg/mL, p = 0.0001)

Effects of diet and exercise and enclomiphene treatment are additiveEnclomiphene treatment combined with diet and exercise increases lean body mass over baseline; higher weight loss in placebo group

THE WOODLANDS, Texas, Aug. 15, 2016  — Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a six month update on results from Repros’ ongoing 15 month study of secondary hypogonadal men in which diet and exercise alone is compared to diet and exercise in combination with enclomiphene treatment. There are two active arms, one dosing men with 12.5 mg of enclomiphene and the other with 25 mg, and one placebo group.

During the recently completed first six month phase of the study, all subjects were provided a commercially available prepared diet along with enrollment in a health club with a personal trainer. In this first phase subjects were asked to attend the health club at least three times per week. All subjects have been assessed for changes in a variety of biochemical markers as well as anatomical markers such as lean body mass and BMI. Changes in responses to three different quality of life questionnaires were also assessed.

During the second six month phase, men will continue their current treatment with enclomiphene or placebo but will no longer be provided the commercial diet. Exercise with the assigned trainer will continue during this period. A second assessment for changes previously monitored will be made and reported.

In the last three months of the study, the subjects will no longer receive treatment but will stay enrolled in the health club, though without a trainer.

Using LC/MS/MS assessments for total T and free T, it was determined diet and exercise alone increased total T from a mean of 264 ng/dL (SD 67) at baseline to 368 ng/dL (SD 116), p = 0.0055, at 6 months but only raised free T from 55.6 pg/mL (SD 18.7) to 57.1 pg/mL (SD 18.2), p = 0.0802.

On the other hand, the 12.5 and 25 mg doses of enclomiphene achieved levels of both total T and free T beyond levels reached without the addition of diet and exercise in previous studies. Again using LC/MS/MS assessments, the 12.5 mg group exhibited an increase in mean morning T from 298 ng/dL (SD 89) to 723 ng/dL (SD 205), p = 0.0002, at six months, while mean morning T for the 25 mg group increased from 255 ng/dL (SD 64) to 864 ng/dL (SD 425), p = 0.0082. Free T by equilibrium method also increased significantly from 62.8 pg/mL (SD 24.1) to 129 pg/mL (SD 47.3), p = 0.0048, for the 12.5 mg group and from 49.0 pg/mL (SD 16.2) to 154 pg/mL (SD 86.2), p = 0.0313, for the 25 mg group. Treatment with enclomiphene produced statistically significantly higher increases in total T (p = 0.0017) and free T (p = 0.0020).

A standard antibody-based assay also showed significant increases for total T in enclomiphene-treated subjects.  Eighty-eight percent (88%) of subjects treated with enclomiphene had a T level in the normal range after six months of treatment while only 23% of placebo-treated subjects were able to normalize T with diet and exercise alone. At all time points, the antibody-based method yielded lower T levels than the LC/MS/MS technique.

Men in all three groups lost weight over the six month evaluation period. Men in the placebo group lost more weight as determined by mean (SD) BMI, 38.1 (2.6) to 33.7 (3.9) at six months compared to 35.5 (3.0) to 33.5 (3.6) for 12.5 mg and 37.4 (3.6) to 35.0 (4.8) for 25 mg. This finding was statistically significant, p<0.05.

Interestingly, subjects treated with enclomiphene showed a statistically significant increase in mean (SD) lean body mass, 1.4 kg (3.0), while the placebo group showed a decrease in lean body mass, 0.3 kg (2.7). This difference between treatment group responses approached borderline statistical significance, p=0.1078.

All groups showed statistically significant improvement in all metabolic parameters tested. However, there was no difference noted between groups.

In terms of the secondary objective of the development of a patient reported outcome (PRO), some encouragement has come from the patient questionnaires incorporated into the protocol. The DISF-SR, a sexual function questionnaire, showed numerical improvement in the drug arm over placebo in the orgasm domain; the IWQOL-LITE, an obesity related questionnaire, showed numerical improvement in the work domain; and the SF-36, a general health questionnaire, showed similar improvement in both the emotional and physical domains. The Company plans to use this data to further research the use of a PRO in this indication.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Forward-Looking Statements

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should” or similar expressions. These statements are based on assumptions that the Company has made in light of the Company’s experience in the industry, as well as the Company’s perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to the the timing and nature of the results of clinical studies and the impact of such results. Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including risks that additional phases of clinical studies may not be successfully undertaken or completed, that the FDA may not ultimately approve the product candidate, the risk that any marketing approvals, if granted, may have significant limitations on use, that even if an NDA is approved, the Company may not be able to successfully commercialize the product candidate, risks relating to the Company’s ability to protect its intellectual property rights and such other risks as are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company’s website at http://www.reprosrx.com.

CONTACT:    
Investor Relations:
Thomas Hoffmann
The Trout Group
(646) 378-2931
thoffmann@troutgroup.com

$CFMS #Clinical #Studies Demonstrate #ConforMIS #iTotal CR, Superior Outcomes/Savings

New clinical study demonstrates potential for ConforMIS iTotal CR customized knee implants to contribute cost savings across episode of care

BEDFORD, Mass., Aug. 15, 2016  — ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that develops, manufactures and sells joint replacement implants that are customized to fit each patient’s unique anatomy, announced today the results from two clinical studies presented at the ICJR Pan Pacific Orthopaedic Congress, August 10 – 13, 2016.

In an independent, prospective, single-center investigator-initiated study of 62 total knee replacement patients in “fast track” surgeries, those who received an iTotal® CR had significantly better outcomes compared to patients who received a traditional “off-the-shelf” implant. Specifically, iTotal CR patients had a significantly shorter length of stay than off-the-shelf patients (1.6 days vs. 2.7 days, p=0.004).  Additionally, a higher proportion of iTotal CR patients were discharged within 24 hours (66% vs. 30%, p=0.006) with a significantly higher proportion of iTotal patients discharged directly to home (97% vs. 80%, p=0.0496) as opposed to a skilled nursing facility. Further, a significantly higher proportion of iTotal patients were able to achieve range of motion greater than or equal to 120˚ (84% vs. 45%, p=0.003).

“I have been using ConforMIS’ iTotal CR for over 5 years and this data reinforces the superior outcomes and quicker recovery that I have observed in my patients,” said Richard Buch, MD, a fellowship-trained orthopedic surgeon with Dallas Limb Restoration Center in Plano, TX and clinical investigator for this study. “Knee replacement patients today are demanding more from their surgery. They want to get home faster and return to their daily activities. In my experience, the ConforMIS iTotal CR allows them to do that more frequently than any other implant I’ve used in my 30 years as an orthopedic surgeon.”

Based on the results of the study and other published economic data, Dr. Buch concluded that ConforMIS iTotal CR has the potential to save hospitals approximately $2,200 per patient. The recent rollout of the Comprehensive Care for Joint Replacement (CJR) model has incentivized hospitals to better manage costs and care coordination for knee replacement patients. Under the CJR model, which has been implemented in 67 Metropolitan Statistical Areas, the Centers for Medicare & Medicaid Services (CMS) has a stated goal of saving $150 million over 5 years. Two of the most costly components across the entire episode of care for total knee replacements are the initial inpatient hospital stay and the use of rehabilitation facilities after discharge. Based on a previously published cost analysis of length of stay¹, by shortening the average length of hospital stay by 1.1 days compared with off-the-shelf implants, Dr. Buch concluded that there is potential for in-hospital cost savings of approximately $1,100 per patient. Similarly, based on another previously published cost analysis of discharge destination², Dr. Buch concluded that a lower proportion of iTotal patients being discharged to skilled nursing facilities has the potential for an additional savings of approximately $1,100 per patient for a total potential savings of approximately $2,200 per patient.

Separately, in an update to an ongoing multi-center prospective study of 740 consecutively enrolled total knee replacement patients, those who received an iTotal CR implant were significantly faster than patients with an off-the-shelf implant at completing three functional tests of daily living: walking, getting in and out of a chair and walking up and down stairs.  Study investigators used a validated functional test known as the Aggregated Locomotor Function (ALF) test, in which blinded operators assessed patients’ ability to perform these activities of daily living.  Additionally, an analysis using the 2011 New Knee Society Score (KSS) found no statistically significant differences. ConforMIS provided financial support for this study.

“Our current healthcare environment is demanding that its treatments not only improve the lives of patients, but do so at a cost that does not overburden the payer system,” said Philipp Lang, MD, MBA, Chief Executive Officer and President of ConforMIS. “Multiple studies have demonstrated that ConforMIS customized knee replacements offer superior patient outcomes compared to traditional off-the-shelf implants, and now we have additional evidence showing that our iTotal CR system can help reduce some of the biggest cost contributors for total knee replacement by shortening the average length of hospital stay and reducing the proportion of patients discharged to skilled nursing facilities.  We believe our iTotal CR system offers cost savings to the hospital across the entire episode of care.”

1: S.J. Barad, et al., Is a shortened length of stay and increased rate of discharge to home associated with a low readmission rate and cost-effectiveness after primary total knee arthroplasty?, Arthroplasty Today (2015), http://dx.doi.org/10.1016/j.artd.2015.08.003
2. Ramos NL, et al, Correlation Between Physician Specific Discharge Costs, LOS, and 30-day Readmission Rates: An Analysis of 1,831 cases, J Arthroplasty (2014), http://dx.doi.org/10.1016/j.arth.2014.04.005

About ConforMIS, Inc.

ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. ConforMIS offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In recent clinical studies, ConforMIS iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. ConforMIS owns or exclusively in-licenses approximately 500 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.

Cautionary Statement Regarding Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for ConforMIS, including statements about the potential clinical, economic or other impacts and advantages of using customized implants, the potential impact of the CJR model and the potential impact and advantages of our products with respect to the CJR model, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including the potential impact of the CJR model on the healthcare industry in general and us in particular, risks related to results seen in ongoing and future clinical and economic studies of our products, risks related to our estimates regarding the potential market opportunity for our current and future products, our expectations regarding our sales and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent ConforMIS’s views as of the date hereof. ConforMIS anticipates that subsequent events and developments may cause ConforMIS’s views to change. However, while ConforMIS may elect to update these forward-looking statements at some point in the future, ConforMIS specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ConforMIS’s views as of any date subsequent to the date hereof.

CONTACT: 

Investor contact:
Oksana Bradley
ir@conformis.com
(781) 374-5598

Media contacts:
Bill Berry
Berry & Company Public Relations
Bberry@berrypr.com
(212) 253-8881

Lynn Granito
Berry & Company Public Relations
Lgranito@berrypr.com
(212) 253-8881

$MGT Files Definitive Proxy for Upcoming #Shareholder #Meeting

HARRISON, N.Y., Aug. 15, 2016  — MGT Capital Investments, Inc. (NYSE MKT: MGT), today announced that it has filed Form DEF 14A (Definitive Proxy Statement) with the U.S. Securities and Exchange Commission for its upcoming 2016 Annual Meeting of Stockholders. The meeting is now scheduled to take place on September 8, 2016 in order to provide shareholders adequate time to receive and review the proxy and vote their shares accordingly.

The Proxy Statement can be accessed via the Company’s website or at www.sec.gov.

Shareholders as of the record date, July 28, 2016, will have the right to vote by proxy or in person at the Annual Meeting of Stockholders to be held Thursday, September 8, 2016 at 10:00 am Eastern Time at the offices of Sichenzia Ross Friedman Ference LLP located at 61 Broadway, 32nd Floor, New York, NY 10006.

Shareholders of record will receive a notice containing instructions on how to access the shareholder meeting materials, including a proxy form and voting instruction form. Shareholders are urged to carefully review the proxy and accompanying materials as they contain important information regarding proposals being voted on at the shareholder meeting.

About MGT Capital Investments, Inc.
MGT Capital Investments, Inc. (NYSE MKT: MGT) is in the process of acquiring a diverse portfolio of cyber security technologies. With cyber security industry pioneer, John McAfee, at its helm, MGT Capital is positioned to address various cyber threats through advanced protection technologies for mobile and personal tech devices, including tablets and smart phones.  The Company is currently in the process of acquiring D-Vasive, a provider of leading edge anti-spy software, and Demonsaw, a provider of a secure and anonymous file sharing software platform.

MGT Capital intends to change its corporate name to “John McAfee Global Technologies, Inc.” upon closing of the D-Vasive transaction.

For more information on the Company, please visit http://ir.stockpr.com/mgtci.

Forward–looking Statements
This press release contains forward–looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward–looking statements.” MGT’s financial and operational results reflected above should not be construed by any means as representative of the current or future value of its common stock. All information set forth in this news release, except historical and factual information, represents forward–looking statements. This includes all statements about the Company’s plans, beliefs, estimates and expectations. These statements are based on current estimates and projections, which involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include issues related to: rapidly changing technology and evolving standards in the industries in which the Company and its subsidiaries operate; the ability to obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new business, license and sign new agreements; the unpredictable nature of consumer preferences; and other factors set forth in the Company’s most recently filed annual report and registration statement. Readers are cautioned not to place undue reliance on these forward–looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risks and uncertainties described in other documents that the Company files from time to time with the U.S. Securities and Exchange Commission.

Investor Contact
Garth Russell
Managing Director
KCSA Strategic Communications
grussell@kcsa.com
212.896.1250

Media Contact
Tiffany Madison
Director of Corporate Communications
MGT Capital Investments, Inc.
tmadison@mgtci.com
469.236.9569

$PWX to be #Acquired by $GWR for $25.00/share #Cash

Providence and Worcester Railroad Company (NASDAQ:PWX) (the “Company”) announced today that on Friday, August 12, 2016, upon completion of a process to assess strategic alternatives, its Board of Directors approved, and the Company entered into, a definitive merger agreement whereby Genesee & Wyoming Inc. (NYSE:GWR) will acquire the Company for $25.00 per share of common stock, or approximately $126 million, in cash. Under the terms of the merger agreement, immediately prior to the closing all outstanding shares of preferred stock of the Company will be deemed converted into common stock of the Company in accordance with their terms. In connection with entry into the merger agreement, the Robert H. Eder Trust and the Linda Eder Trust, which own a majority of the preferred stock of the Company and approximately 17.3 percent of the common stock of the Company, have entered into a Voting Agreement with Genesee & Wyoming and the Company to vote all of the shares of the preferred stock and common stock owned by the Trusts in favor of the transaction.

The transaction is expected to close in the fourth quarter of 2016 and is subject to approval by the Company’s common and preferred shareholders, satisfaction of certain regulatory approvals and other customary closing conditions.

Robert H. Eder, longtime chairman and CEO of the Company, said: “Becoming part of the Genesee & Wyoming family with its record of emphasis on safety and investment in its rail infrastructure ensures that our Company will continue to provide the quality of service which our customers and the communities we serve have enjoyed over the 40+ years since we re-commenced independent operations while at the same time continuing and improving on our programs to promote employee and community safety.”

Additional Information and Where to Find It

In connection with the transaction the Company will file relevant materials with the Securities and Exchange Commission (the “SEC”), including a proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the proxy statement and proxy card to each shareholder entitled to vote at the special meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT THE COMPANY FILES WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE TRANSACTION. The definitive proxy statement, the preliminary proxy statement and other relevant materials in connection with the transaction (when they become available), and any other documents filed by the Company with the SEC, may be obtained free of charge at the SEC’s website (http://www.sec.gov) or at the Company’s website (http://www.pwrr.com) or by writing to the Providence and Worcester Railroad Company, 75 Hammond Street, Worcester, Ma. 01610, Attn: Charles D. Rennick, General Counsel.

Participant Information

The Company and its directors and executive officers are participants in the solicitation of proxies from the Company’s shareholders with respect to the transaction. Information about the Company’s directors and executive officers and their ownership of the Company’s common stock is set forth in the Company’s proxy statement on Schedule 14A filed with the SEC on March 21, 2016. To the extent that holdings of the Company’s securities have changed since the amounts printed in the Company’s proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the identity of the participants and their direct or indirect interests in the transaction, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the transaction.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the proposed transaction, including benefits of the transaction, and the anticipated timing of the transaction. These forward-looking statements generally are identified by the words “believe”, “project”, “expect”, “anticipate”, “estimate”, “future”, “strategy” , “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result”, and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the Company’s business and the price of the Company’s common stock, (ii) the failure to satisfy the conditions to the consummation of the transaction, including the approval of the merger agreement by the shareholders of the Company and the receipt of certain governmental and regulatory approvals, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) the effect of the announcement or pendency of the transaction on the Company’s business relationships, operating results and business generally, (v) risks that the proposed transaction disrupts current plans and operations of the Company and potential difficulties in Company employee retention as a result of the transaction, (vi) risks related to diverting management’s attention from the Company’s ongoing business operations, and (vii) the outcome of any legal proceedings that may be instituted against the Company related to the merger agreement or the transaction. In addition please refer to the documents that the Company files with the SEC on Forms 10-K, 10-Q and 8-K. These filings identify and address other important risks and uncertainties that could cause events and results to differ materially from those contained in the forward-looking statements set forth in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements and the Company assumes no obligation, and does not intend, to update or revise these forward-looking statements, whether as result of new information, future events, or otherwise.

$EXPI #Record #Q2 #Growth & #Revenue on Strength of #AgentOwned #Cloud #Brokerage

Revenue Up 137%; Agent Count Up 111%

BELLINGHAM, WA–(August 15, 2016) – eXp World Holdings, Inc. (OTCQB: EXPI), today released its second quarter financial results.

Financial Highlights

• Revenues for the quarter of $13,282,028, up 137% from $5,584,963 year over year;
• Agent Count for Real Estate Division up 111% over Q2 2015 to 1,400 agents (as of June 30);
• Cash and cash equivalents at June 30, 2016 up 207% vs June 30, 2015;
• The Company reported a GAAP Net Loss of $6,005,907 which was primarily attributable to a $6.0 million non-cash compensation expense resulting from the required accounting treatment of stock options that were issued prior to EXPI being a public company.*

The increase in revenue is a direct result of the increased sales agent base and higher sales volume realized by the Company’s real estate brokerage division, eXp Realty, The Agent-Owned Cloud Brokerage®

Today, eXp Realty has more than 1,580 real estate professionals across 40 states, The District of Columbia, and Alberta, Canada.

Glenn Sanford, the Company’s Chairman and Chief Executive Officer, commented on the Company’s performance, “eXp Realty continues to experience accelerated growth in agent count and in revenues as a result of our commitment to agent ownership, agent support, and agent engagement.”

*Note: As explained in the Company’s Quarterly Report on Form 10-Q which can be found at: https://www.sec.gov/Archives/edgar/data/1495932/000101968716007240/exp_10q-063016.htm, the Company accounts for stock options issued prior to September 2013 using the intrinsic value method of accounting. As a result, the Company is required to remeasure the intrinsic value of these outstanding options at each reporting date and record a non-cash compensation expense or benefit to reflect the change in intrinsic value. As our stock price has continued to increase during the six month period ending June 30, 2016 this has triggered an increase in intrinsic value of these options resulting in a non-cash compensation expense of $6.0 million to be recognized during this period.

About eXp World Holdings, Inc.

eXp World Holdings, Inc. is the holding company for a number of companies most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage®, as a full-service real estate brokerage providing 24/7 access to collaborative tools, training, and socialization for real estate brokers and agents through its 3-D, fully-immersive, cloud office environment. eXp Realty, LLC and eXp Realty of Canada, Inc. also feature an aggressive revenue sharing program that pays agents a percentage of gross commission income earned by fellow real estate professionals who they attract into the Company.

eXp World Holdings, Inc. also owns 89.4% of First Cloud Mortgage, Inc. a Delaware corporation launched in 2015 and now licensed to originate mortgages in Arizona, California, New Mexico, Virginia and Texas. First Cloud Mortgage has positioned itself as a Planet Friendly Mortgage Company via the purchase of carbon offsets for homeowners offsetting the first year of the Carbon Footprint of the typical home on each mortgage originated through First Cloud Mortgage, Inc.

As a publicly-traded company, eXp World Holdings, Inc. uniquely offers professionals within its ranks opportunities to earn equity awards for production and contributions to overall company growth.

For more information you can follow eXp World Holdings, Inc. on Twitter, LinkedIn, Facebook, YouTube, or visit eXpWorldHoldings.com. For eXp Realty please visit: eXpRealty.com and for First Cloud Mortgage, Inc. check out FirstCloudMortgage.com.

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to revise or update them. These statements include, but are not limited to, statements about the Company’s expansion, revenue growth, operating results, financial performance and net income changes. Such statements are not guarantees of future performance. Important factors that may cause actual results to differ materially and adversely from those expressed in forward-looking statements include changes in business or other market conditions; the difficulty of keeping expense growth at modest levels while increasing revenues; and other risks detailed from time to time in the Company’s Securities and Exchange Commission filings, including but not limited to the most recently filed Annual Report on Form 10-K.

 

Investor Relations Contact Information:
Glenn Sanford
Chairman & CEO
eXp World Holdings, Inc.
glenn@expworldholdings.com
360-389-2426

Trade and Media Contact Information:
Jason Gesing
President
eXp World Holdings, Inc.
jason@expworldholdings.com
617-970-8518

$BKEPP to Participate in $C #Citi MLP / #MidstreamInfrastructureConference

Blueknight Energy Partners, L.P. (“BKEP” or the “Partnership”) (NASDAQ: BKEP) (NASDAQ: BKEPP), announced today that Mark Hurley, Chief Executive Officer, Brian Melton, Vice-President of Business Development and Alex Stallings, Chief Financial Officer will attend the Citi One-on-One MLP/Midstream Infrastructure Conference in Las Vegas, Nevada, August 17 – 18, 2016.

The materials used during the conference will be accessible in the Investors section of BKEP’s website at www.bkep.com on Wednesday, August 17, 2016.

About Blueknight Energy Partners, L.P.

BKEP owns and operates a diversified portfolio of complementary midstream energy assets consisting of approximately 7.4 million barrels of crude oil storage located in Oklahoma and Texas, approximately 6.6 million barrels of which are located at the Cushing, Oklahoma Interchange, approximately 985 miles of crude oil pipeline located primarily in Oklahoma and Texas, approximately 240 crude oil transportation and oilfield services vehicles deployed in Kansas, Oklahoma, and Texas and approximately 8.2 million barrels of combined asphalt product and residual fuel oil storage located at 45 terminals in 24 states. BKEP provides integrated services for companies engaged in the production, distribution and marketing of crude oil, asphalt and other petroleum products. BKEP is headquartered in Oklahoma City, Oklahoma. For more information, visit the Partnership’s Web site at www.bkep.com.

$YOD #Closes $4 Million #Investment from #HarvestAlternative

$ARWR #Closes $45 Million #PrivateOffering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. Gross proceeds were $45 million. Approximately 7.63 million shares of common stock were issued at a price of $5.90 per share.

Cantor Fitzgerald & Co. acted as sole placement agent for the private offering. Trout Capital LLC and Chardan Capital Markets LLC acted as financial advisors.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued and sold in the private placement.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.

For more information please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

$STKS Enters into #Loan Agreement for $3 Million

The ONE Group Hospitality, Inc. (“The ONE Group”) (Nasdaq:STKS) today announced that it has entered into a loan agreement with Anson Investments Master Fund LP (“Anson”) for $3 million, through an unsecured promissory note. The unsecured promissory note bears interest at a rate of 10% per annum, payable quarterly commencing September 30, 2016, until its maturity date of August 11, 2021. The funds will be used for development.

Pursuant to the loan agreement, The ONE Group issued a common stock purchase warrant to Anson to purchase 300,000 shares of The ONE Group’s common stock at an exercise price of $2.61 per share.

Further information with respect to the loan, the unsecured promissory note and the warrant will be contained in a Current Report on Form 8-K that The ONE Group intends to file with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About The ONE Group

The ONE Group (Nasdaq:STKS) is a global hospitality company that develops and operates upscale, high-energy restaurants and lounges and provides hospitality management services for hotels, casinos and other high-end venues both nationally and internationally. The ONE Group’s primary restaurant brand is STK, a modern twist on the American steakhouse concept with locations in major metropolitan cities throughout the U.S. and Europe. STK Rebel, a more accessibly priced STK with a broader menu, is an extension of the STK brand. The ONE Group’s food and beverage hospitality services business, ONE Hospitality, provides the development, management and operations for premier restaurants and turn-key food and beverage services within high-end hotels and casinos. Additional information about The ONE Group can be found at www.togrp.com.

Cautionary Statement on Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements, including but not limited to, (1) The ONE Group’s ability to open new restaurants and food and beverage locations in current and additional markets, obtain additional financing, grow and manage growth profitably, maintain relationships with suppliers and obtain adequate supply of products and retain its key employees; (2) factors beyond the control of The ONE Group that affect the number and timing of new restaurant openings, including weather conditions and factors under the control of landlords, contractors and regulatory and/or licensing authorities; (3) changes in applicable laws or regulations; (4) the possibility that The ONE Group may be adversely affected by other economic, business, and/or competitive factors; and (5) other risks and uncertainties indicated from time to time in The ONE Group’s filings with the Securities and Exchange Commission, including The ONE Group’s Annual Report on Form 10-K filed on March 30, 2016 and our Quarterly Report on Form 10-Q filed on May 16, 2016.

Investors are referred to the most recent reports filed with the Securities and Exchange Commission by The ONE Group Hospitality, Inc. Investors are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

ICR
Michelle Epstein, 646-277-1224

$ENDP Announces #OPANA ER #Regulatory #Update

DUBLIN, Aug. 12, 2016  — Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that based on an August 11, 2016 discussion with the U.S. Food and Drug Administration (FDA), the Company has decided to withdraw its supplemental New Drug Application (sNDA) relating to specific abuse deterrent labeling for OPANA® ER without prejudice to re-filing. The Company plans to continue collecting and analyzing epidemiological data relating to OPANA® ER. Endo’s financial projections for 2016 did not assume approval of the sNDA.

“We anticipate the generation of additional data and we will seek collaboration with FDA to appropriately advance OPANA® ER,” said Sue Hall, Ph.D., Executive Vice President, Chief Scientific Officer and Global Head of Research & Development and Quality at Endo. “We believe in the ability of OPANA® ER to continue making a difference in the lives of appropriate patients and remain committed to safely and effectively addressing the needs of the pain patient community.”

OPANA® ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatment options are inadequate. The sNDA for OPANA® ER, which is formulated using INTAC® Technology, included studies designed to evaluate the abuse deterrence of the formulation. INTAC® Technology increases tablet hardness using a high molecular weight polymer (polyethylene oxide).

About Endo International plc

Endo International plc is a global specialty pharmaceutical company focused on improving patients’ lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including, but not limited to, the statements by Dr. Hall. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo’s expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in Endo’s periodic reports filed with the U.S. Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval (“SEDAR”), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K.  Additional information about Endo is available on the World Wide Web at www.endo.com or you can contact the Endo Investor Relations department by calling (484) 216-0000.

$HPJ Enters Into #EquityPurchaseAgreement to Expand #EV Presence

SAN FRANCISCO and SHENZHEN, China, Aug. 12, 2016  — Highpower International, Inc. (NASDAQ: HPJ), (“Highpower,” or the “Company”) a developer, manufacturer, and marketer of lithium and nickel-metal hydride (Ni-MH) rechargeable batteries, and a battery management systems and battery recycling provider, today announced that its wholly-owned subsidiary, Huizhou Highpower Technology Co., Ltd, has entered into an agreement (“Agreement”) to acquire up to 50% equity interest in Huizhou Yipeng Energy Technology Co., Ltd. (“Huizhou Yipeng”), an electric vehicle power battery system solutions provider specializing in the plug-in hybrid electric vehicle (PHEV) and electric vehicle (EV) bus market in China.

Pursuant to the Agreement, the Company will invest RMB114.75 million (approximately $17.3 million) consisting of an aggregate of $5.2 million in cash and $12.1 million of power battery equipment into Huizhou Yipeng for a 50% equity interest. On August 10, 2016, the Company consummated the first purchase of  30.4% for RMB 15 million in cash (approximately $2.3 million) and power equipment equivalent to RMB 45 million (approximately $6.8 million). The purchase of the remaining equity interest of 14.6% for RMB 19.75 million in cash (approximately $2.9 million) and power equipment equivalent to RMB 35 million (approximately $5.3 million) is scheduled to close prior to November 5, 2016 subject to Huizhou Yipeng being approved prior to October 31, 2016 to be listed in the catalogue of industrial Standards of Auto Mobile Power Battery Cell, which is formulated by the Ministry of Industry and Information Technology of the People’s Republic of China. The Company intends to fund the equity purchase with cash on hand, expected future cash flow, and if needed, approximately $2.0 million in borrowings under existing credit arrangements. Prior to entering into the Agreement, Highpower already held an existing 5% equity interest in Huizhou Yipeng. Highpower also has the right to purchase from existing Huizhou Yipeng shareholders additional equity for $0.4, million which would give Highpower a total of 51% equity interest in Huizhou Yipeng.

Huizhou Yipeng was founded in Huizhou City, Guangdong Province in January 2014, and is a new high-tech enterprise focusing on lithium-ion power battery systems in new energy vehicle application. Mr. Hongze Yu, the CEO of Huizhou Yipeng, has over twenty years of experience in driving growth strategy for companies in the Chinese-vehicle industry. Prior to Huizhou Yipeng, Mr. Yu was co-founder of Beijing JAYA Technology Co., Ltd., a company specializing in smart transportation started in 2005.

Management Commentary

Mr. George Pan, Chairman and CEO of Highpower International, commented, “We are pleased to announce our strategic investment in Huizhou Yipeng, which has established an industry leading position in China in the PHEV and EV bus market, which has experienced growth in recent years in power battery system. We have worked with their management team for over two years, as Huizhou Yipeng has been a customer of Highpower and we have collaborated on several projects in past.  We had a high degree of comfort after establishing this relationship to move forward and take a position in the company, and believe that our combined resources will allow Huizhou Highpower to expand more rapidly in the PHEV and EV power battery market in China and help extend Highpower’s industrial chain.”

About Huizhou Yipeng Energy Technology Co., Ltd.

Yipeng Energy Technology Co., Ltd. was founded in Huizhou City, Guangdong Province in January 2014, and is a new high-tech enterprise focusing on lithium-ion power battery systems in new energy vehicle application. Huizhou Yipeng is a developer, manufacturer, and marketer of the plug-in hybrid and pure electric vehicle fast charge lithium-ion battery systems. Huizhou Yipeng has obtained the ISO / TS16949: 2009 certification in 2015, and its fast charge battery power system has been widely used in public transportation vehicles across China. Huizhou Yipeng has been recognized by EATON Corporation in the US and has also become the standard power battery system supplier to HIGER, a top brand bus in China. Huizhou Yipeng mainly focuses on the PHEV and fast charge EV bus market, achieving over 50 million kilometers’ safe running record. For more information about Huizhou Yipeng, please go to (in Mandarin): http://www.kyipeng.com/

About Highpower International, Inc.

Highpower International was founded in 2001 and produces high-quality Nickel-Metal Hydride (Ni-MH) and lithium-based rechargeable batteries used in a wide range of applications such as electric buses, bikes, energy storage systems, power tools, medical equipment, digital and electronic devices, personal care products, and lighting. Highpower’s target customers are Fortune 500 companies, and top 10 companies in each vertical segment. With advanced manufacturing facilities located in Shenzhen, Huizhou, and Ganzhou of China, Highpower is committed to clean energy technology, not only in the products it makes, but also in the processes of production. The majority of Highpower International’s products are distributed to worldwide markets mainly in the United States, Europe, Japan, China and Southeast Asia.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements  can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology, and include discussions of the Company’s future performance, operations and products.  Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company’s actual results to differ materially from the results expressed or implied by such statements, including, the occurrence of any event, change or other circumstances that could give rise to the termination of the Agreement; the inability to complete the transaction within the expected time period or at all, including due to Huizhou Yipeng’s failure to be approved for listing in the catalogue of industrial Standards of Auto Mobile Power Battery Cell, or the failure to satisfy other conditions to completion of the acquisition; risks related to disruption of management’s attention from the ongoing business operations due to the acquisition; the effect of the announcement of the acquisition on Highpower’s or Huizhou Yipeng’s relationships with their respective customers and lenders or on their  operating results and businesses generally, inability to achieve the expected benefits resulting from the acquisition, such as expansion of Huizhou’s Yipeng’s business; our ability to successfully expand sales of our lithium battery product in the mobile device market and our ability to effectively compete in that market. For a discussion of these and other risks and uncertainties see “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s public filings with the SEC.  Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

CONTACT:
Highpower International, Inc.
Sherry Chen
+86-755-8968-6521
ir@highpowertech.com

INVESTOR RELATIONS:
The Equity Group Inc.
In China
Katherine Yao, Senior Associate
+86-10-6587-6435
kyao@equityny.com

In U.S.
Adam Prior, Senior Vice President
(212) 836-9606
aprior@equityny.com

$NVGN Submits #IND to #FDA for #Cantrixil in #Ovarian #Cancer

– Cantrixil (TRX-E-002-1) is Novogen’s lead development candidate, and is being developed as a therapy for patients with ovarian cancer – Investigational New Drug (IND) application is the key regulatory filing to initiate clinical trials in the United States – First-in-human (FIH) phase I study remains on track for initiation in the fourth calendar quarter of 2016, in line with previous guidance

SYDNEY, Aug. 11, 2016  — Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for Cantrixil (TRX-E-002-1) in ovarian cancer.

The IND is a detailed regulatory filing which is required to initiate clinical studies in the United States. It has been compiled over the past twelve months, following a decision to move Cantrixil into clinical development at the Company’s strategic pipeline review in August 2015.

The IND submission includes a comprehensive package of data, encompassing preclinical pharmacology and toxicity, manufacturing, quality control and clinical development plans. Novogen will be able to move forward to the next step of setting up the clinical trials program thirty days after submission, unless FDA reviewers have questions or concerns which cannot be resolved during that time.

Dr Kimberley Lilischkis, Director of Clinical & Regulatory Affairs at Novogen, commented, “The Cantrixil IND is a critical step on the path to the clinic. We will work closely with the FDA to resolve any queries they may have. Following that, we expect to initiate the study swiftly in the last quarter of 2016, with participation from centres in the US and Australia.”

Cantrixil is a first-in-class development candidate which is being studied as a therapy for ovarian cancer, administered directly into the abdominal cavity via the intra-peritoneal route. Preclinical data has shown broad-based evidence of anti-tumour activity in animal models of ovarian cancer,[1] and a toxicology program conducted under GLP (Good Laboratory Practice (GLP) has demonstrated a toxicity profile that appears appropriate for use in humans at therapeutic doses.[2]

Dr James Garner, CEO of Novogen, added, “This is an important milestone in Novogen’s transition to a clinical stage drug development company. I am delighted that the team has succeeded in delivering on schedule, in accordance with our prior guidance of an August 2016 submission. The Cantrixil trial has received strong interest from clinicians in Australia and the United States. The team is working with Quintiles, our contract research organisation, to select and initiate the most appropriate trial sites and prepare for the phase I study.”

About the Cantrixil (TRX-E-002-1) development candidate

Cantrixil is a cyclodextrin-based formulation of the active ingredient, TRX-E-002-1, which has shown in vitro and in vivo anti-cancer activity in a range of tumour types. The Company anticipates that, if approved, the drug product would be used as an intra-peritoneal chemotherapy, either alone or in combination with other agents, and in one or more cancers of the abdominal or pelvic cavity (e.g. ovarian, uterine, colorectal or gastric carcinomas). A first-in-human clinical study is planned to commence in the fourth quarter of 2016.

About Novogen Limited

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an oncology-focused biotechnology company based in Sydney, Australia. Novogen has two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) with the potential to yield first-in-class agents across a range of oncology indications. The three lead molecules Cantrixil, Anisina, and Trilexium are in preclinical development, with the most advanced molecule, Cantrixil, slated to enter clinical trials in late 2016. For more information, please visit: www.novogen.com

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as “expects,” “appear,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “should,” “would,” “may,” “target,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to Cantrixil, Anisina, Trilexium, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, Cantrixil, Anisina, Trilexium, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, Cantrixil, Anisina, Trilexium, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil, Anisina, Trilexium, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

[1] AB Alvero, A Heaton, E Lima, et al. (2016). Molecular Cancer Therapeutics, 15(6):1279-90 (June 2016)

[2] K Lilischkis, A Heaton, A Alvero, et al. (2016). Abstract LB201, Annual Meeting of the American Association of Cancer Research (New Orleans, LA)

$MDVX Releases Letter to Shareholders, #DenerveX

Medovex Corp.
Jason Assad
470-505-9905
Email Contact

$ASCMA Launches #Exclusive #Discounts For #AARP #Members

International security company provides benefits for members of prominent non-profit

DALLAS, Aug. 11, 2016  — Monitronics, a subsidiary of Ascent Capital Group, Inc. (NASDAQ: ASCMA) and leading international home security alarm monitoring company headquartered in Dallas, today launched a relationship with AARP that will offer its 38 million members an exclusive discount on professionally installed residential security alarms and monitoring.

New customers with a valid AARP membership number will receive equipment and free activation up to $149, as well as $5 off their monthly monitoring fee. Existing Monitronics customers with a valid AARP membership can receive a 25% discount on additional equipment, including medical monitoring devices, smart video doorbells, and other smart home technology.

“We are thrilled at the opportunity to bring safety and security to one of our country’s fastest growing age segments,” said Jeff Gardner, Monitronics President and CEO. “AARP has a highly regarded social mission and a well-deserved reputation as an advocate for today’s 50-plus population, and we are incredibly pleased to be part of this strategic relationship.”

Security is top of mind for many AARP members, and Monitronics delivers world-class products, customer service, and innovative smart home solutions to its 1.2 million customers. As the new exclusive provider of professionally installed residential security and monitoring for AARP members, the company is excited to extend these benefits to this growing population at a discounted rate.

“AARP is pleased to announce this new relationship with Monitronics, which demonstrates a commitment to providing customers with the very best security the industry has to offer. Security is important to our members, who are busy exploring the world and taking on new challenges every day,” said Victoria Borton, Vice President, Lifestyle Products for AARP Services, Inc. “This program can give our members peace of mind while they pursue their goals, helping to keep them free of worry about their homes and property, and delivering immediate help in the case of an emergency.”

To take advantage of Monitronics’ residential security installation and monitoring offer, please visit the AARP Member Advantages website, AARPAdvantages.com. AARP Member Advantages is a collection of discounts, products and services available to AARP’s millions of members through third parties, not by AARP or its affiliates.

About Monitronics International, Inc.
A subsidiary of Ascent Capital Group, Inc. (NASDAQ: ASCMA), Monitronics is one of the nation’s largest and fastest-growing home security alarm monitoring companies. Headquartered in Dallas, it provides monitored home and business security system services to over 1 million residential customers and commercial client accounts through its network of independent Authorized Dealers in the U.S., Canada and Puerto Rico.

About AARP
AARP is a nonprofit, nonpartisan organization, with a membership of nearly 38 million that helps people turn their goals and dreams into ‘Real Possibilities’ by changing the way America defines aging. With staffed offices in all 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, AARP works to strengthen communities and promote the issues that matter most to families such as healthcare security, financial security and personal fulfillment. AARP also advocates for individuals in the marketplace by selecting products and services of high quality and value to carry the AARP name.  As a trusted source for news and information, AARP produces the world’s largest circulation magazine, AARP The Magazine and AARP Bulletin. AARP does not endorse candidates for public office or make contributions to political campaigns or candidates. To learn more, visit www.aarp.org or follow @aarp and our CEO @JoAnn_Jenkins on Twitter.

About AARP Services Inc.
AARP Services, Inc., founded in 1999, is a wholly-owned taxable subsidiary of AARP. AARP Services manages the provider relationships for and performs quality control oversight of the wide range of products and services that carry the AARP name and are made available by independent providers as benefits to AARP’s millions of members. The provider offers currently span health products, financial products, travel and leisure products, and life event services. Specific products include Medicare supplemental insurance; credit cards, auto and home, mobile home and motorcycle insurance, life insurance and annuities; member discounts on rental cars, cruises, vacation packages and lodging; special offers on technology and gifts; pharmacy services and legal services. AARP Services also engages in new product development activities for AARP and provides certain consulting services to outside companies.

Contact: Lindsay Lougee
Monitronics International
Tel: 972-243-7443, ext. 73121
E-mail: llougee@monitronics.com
www.monitronics.com

$MCEP Announces #Closing of #Permian #Acquisition

TULSA, Aug. 11, 2016  — Mid-Con Energy Partners, LP (NASDAQ:MCEP) (“Mid-Con Energy” or the “Partnership”) through its wholly owned subsidiary, Mid-Con Energy Properties, LLC, today announced closing of its previously announced acquisition of oil and natural gas properties in Nolan County, Texas, for approximately $19.5 million. The acquisition is subject to customary post-closing adjustments based on an effective date of June 1, 2016.

PERMIAN ACQUISITION HIGHLIGHTS

• Mid-Con Energy acquires ~96% average working interest
• Properties include 27 producing wells, 11 injection wells, and 3 inactive wells
• Net proved reserves of ~1.5 MMBoe audited by Cawley, Gillespie and Associates, Inc.
• Reserves ~57% proved developed producing and ~99% oil with a reserve-to-production ratio of ~11.2 years
• Average net daily production of 368 Boe/d (~96% oil) calculated based on trailing three-month average ended June 30, 2016
• Historical lease operating expenses average approximately $12/Boe based on trailing three-month period ended June 30, 2016
• Production taxes approximate 4.6%

CLASS A CONVERTIBLE PREFERRED UNITS
In conjunction with the acquisition, on August 11, 2016, Mid-Con Energy closed its previously announced private offering (the “Offering”) of $25.0 million aggregate principal amount of Class A Convertible Preferred Units (“Preferred Units”) to investors led by John Goff and including, among others, Mid-Con Energy III, LLC, an affiliate of Mid-Con Energy’s general partner, Bonanza Capital, and Swank Capital.  The Partnership used net proceeds from the Offering to fund its Permian acquisition, and excess net proceeds will be used for general partnership purposes, including repayment of borrowings outstanding under Mid-Con Energy’s revolving credit facility.

The Preferred Units were issued at a price of $2.15 per Preferred Unit (the “Unit Purchase Price”). The Partnership will pay holders of the Preferred Units (“Holders”) a cumulative, quarterly distribution in cash at an annual rate of 8.00% or, under certain circumstances, in additional Preferred Units, at an annual rate of 10.00%.  At any time after the six-month anniversary and prior to the fifth anniversary of the closing date of the Offering, each Holder may elect to convert all or any portion of such Holder’s Preferred Units into common units representing limited partner interests in Mid-Con Energy on a one-for-one basis. On the fifth anniversary of the closing date of the Offering, each Holder may elect to cause the Partnership to redeem all or any portion of such Holder’s Preferred Units for cash at the Unit Purchase Price, and any remaining Preferred Units will thereafter be converted to Common Units on a one-for-one basis.

$140 MILLION CONFORMING BORROWING BASE
Mid-Con Energy and its lenders executed Amendment No. 10 to the Partnership’s credit agreement on August 11, 2016, increasing the conforming borrowing base of the Partnership’s senior secured revolving credit facility to $140 million.  Pro forma for net proceeds from the Permian acquisition and the Offering, debt outstanding will be approximately $133 million. Mid-Con Energy’s next regularly scheduled bi-annual redetermination is expected to occur on or about November 1, 2016.

ABOUT MID-CON ENERGY PARTNERS, LP
Mid-Con Energy is a publicly held Delaware limited partnership formed in July 2011 to own, acquire, exploit and develop producing oil and natural gas properties in North America, with a focus on Enhanced Oil Recovery.  Mid-Con Energy’s core areas of operation are located in Southern Oklahoma, Northeastern Oklahoma, the Gulf Coast, and the Permian.  For more information, please visit Mid-Con Energy’s website at www.midconenergypartners.com.

FORWARD-LOOKING STATEMENTS
This press release includes “forward-looking statements” — that is, statements related to future, not past, events within meaning of the federal securities laws. Forward-looking statements are based on current expectations and include any statement that does not directly relate to a current or historical fact. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate,” “believe,” “estimate,” “intend,” “expect,” “plan,” “project,” “should,” “goal,” “forecast,” “guidance,” “could,” “may,” “continue,” “might,” “potential,” “scheduled,” or “will” or other similar words. These forward-looking statements involve certain risks and uncertainties and ultimately may not prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. For further discussion of risks and uncertainties, you should refer to Mid-Con Energy’s filings with the Securities and Exchange Commission (“SEC”) available at www.midconenergypartners.com or www.sec.gov. Mid-Con Energy undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement and our SEC filings. Please see the risks and uncertainties detailed in the “Forward-Looking Statements” of our public filings.

INVESTOR RELATIONS CONTACT
IR@midcon-energy.com
(918) 743-7575

$SGI to be #Acquired by $HPE Amid #BigData Analytics Push

$QRHC Announces 1-for-8 #Reverse #StockSplit

$GEMP Announces #Closing of #IPO

NORTHVILLE, Mich., Aug. 10, 2016  — Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease) today announced the closing of its previously announced initial public offering of 3,000,000 shares of its common stock at a price to the public of $10.00 per share. In addition, Gemphire has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.  The shares began trading on the NASDAQ Global Market on August 5, 2016 under the ticker symbol “GEMP”.  The gross proceeds to Gemphire from the initial public offering were $30 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Jefferies LLC and RBC Capital Markets, LLC acted as joint book-running managers for the offering.  Canaccord Genuity Inc. acted as co-lead manager for the offering and Laidlaw & Company (UK) Ltd. and LifeSci Capital LLC acted as co-managers.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 4, 2016.  The offering was made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; or from RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact:
David Pitts
Argot Partners
212-600-1902

$VTVT Positive #Topline #Results Phase 2b #TTP399 Study in #Type2Diabetes

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

VTV THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B STUDY OF GLUCOKINASE ACTIVATOR TTP399 IN TYPE 2 DIABETES

Novel glucokinase activator shows sustained meaningful reduction in HbA1c with well-tolerated treatment regimen

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced positive topline results from a placebo and active-comparator-controlled Phase 2b clinical study of TTP399, a liver-selective glucokinase activator under development for the treatment of Type 2 diabetes.

Topline results showed achievement of the primary endpoint of statistically significant change from baseline in HbA1c at 6 months of daily administration of 800 mg of TTP399. The reduction in HbA1c was dose-dependent and sustained throughout the duration of the study. TTP399 was also found to be well-tolerated. Further analysis of the data is ongoing.

“We are extremely pleased with these findings from our Phase 2b study of TTP399,” commented Steve Holcombe, President and CEO of vTv Therapeutics. “These results show that a glucokinase activator with hepatic selectivity may lead to a meaningful reduction in HbA1c on a sustained basis. We are enthusiastic about advancing TTP399 to the next stage of development.”

“We now have a glucokinase activator that appears to improve glucose control in a safe and sustained manner. I believe the Phase 2 results suggest that TTP399 may become a significant treatment option in diabetes care,” said Dr. John Buse, Director of the North Carolina Translational and Clinical Sciences Institute and of the Diabetes Center at the University of North Carolina School of Medicine and a member of the vTv Therapeutics Scientific Advisory Board.

The Phase 2b AGATA (Add Glucokinase Activator to Target A1c) is a six-month, double-blind, placebo- and active-controlled parallel group trial in 190 patients with Type 2 diabetes on a stable dose of metformin. The primary endpoint was change from baseline in HbA1c at six months.

A manuscript with more details is in preparation and will be submitted for publication to a major medical journal.

About Glucokinase and TTP399

Glucokinase (GK) is a key regulator of glucose homeostasis. GK is a genetically validated target. Loss of function mutations in the gene coding for GK can cause hyperglycemia and Type 2 diabetes.

Activation of GK, a mechanism of action that is distinct from existing Type 2 diabetes treatments, increases GK activity thereby improving glycemic control in Type 2 diabetes. Previous attempts to develop GK activators were unsuccessful due to lack of sustained clinical effect, and increased incidence of hypoglycemia and hyperlipidemia. TTP399 is an orally bioavailable small molecule GK activator. Unlike previous approaches, TTP399 targets GK activation only in the liver and does not appear to disrupt the interaction between GK and glucokinase regulatory protein (GKRP). TTP399 was discovered by vTv scientists using its proprietary translational technology platform.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Investors
The Trout Group
Michael Gibralter, 646-378-2938
mgibralter@troutgroup.com
or
Media
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com

$AAU #HighGrade Zone at #Tuligtic; 1m @ 6.19 g/t #Gold 1250 g/t #Silver

VANCOUVER, BC–(August 10, 2016) – Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX: AMM) (NYSE MKT: AAU) is pleased to announce assay results from Almaden’s ongoing exploration and development program at the Company’s Tuligtic project, Mexico. Drill hole TU-16-318A was drilled from the bottom of hole TU-13-318 which in 2013 stopped short of the vein zone reported today. By deepening this hole the Company was able to confirm a zone of veining intersected up-dip in hole TU-11-056, which in 2011 hit two high grade veins that returned 1.26 meters of 2.45 g/t gold and 854 g/t silver and 0.95 meters of 13.86 g/t gold and 2577 g/t silver respectively. Results have also been received from hole TU-16-462 drilled above TU-11-056. This hole also intersected the vein zone and hit two intervals, 0.74 meters of 1.26 g/t gold and 203 g/t silver and 0.52 meters of 0.28 g/t gold and 297 g/t silver respectively.

The mineralisation reported today confirms the presence of additional important zones of veining immediately adjacent to the Ixtaca Zone and points to the exploration potential of the project in general. The Ixtaca Zone was discovered in 2010 beneath a large area of largely barren clay alteration which has been confirmed subsequently to represent the upper portions of a gold and silver bearing epithermal vein system. Since the discovery Almaden has focussed its efforts on the development of the Ixtaca Zone, however today’s results clearly show the potential for additional mineralisation, not only proximal to the deposit, but more broadly project wide beneath the high level clay alteration.

Currently, geotechnical drilling relating to ongoing pre-feasibility work is nearing completion while exploration drilling is ongoing and further exploration results will be reported once received. Recently the Company released a positive Preliminary Economic Assessment (“PEA”) on the Ixtaca deposit (see news release dated December 9th, 2015). Approximately 97% of the mineral resources incorporated into the updated PEA mine plan were in the Measured and Indicated categories.

J.D. Poliquin, chairman of Almaden stated, “Today’s results once again show the presence of the high grade veins on the Tuligtic project. While we are now focussed on developing the Ixtaca deposit into a significant precious metals producer in Mexico, and are currently busy with engineering work and studies towards producing a PFS, we are also conducting exploration drilling to test for additional resource potential.”

About the Ixtaca Deposit PFS Program
Development related activities are currently underway, including advanced engineering and environmental baseline studies to meet the requirements of a PFS and the submittal of an environmental permit application and risk assessment to the Mexican regulatory agency responsible for mine permitting. To date Almaden has completed or initiated the following studies:

• Hydrologic studies including the drilling of water test wells and installation of hydrologic equipment for baseline monitoring of existing subsurface water flow and quality on the project site (installation complete, monitoring ongoing);
• Baseline surface water quality and flow measurements (monitoring ongoing);
• Geochemical characterization of rock materials (complete);
• Condemnation drilling of areas where mine infrastructure is planned (complete);
• Geotechnical drilling to confirm foundation, footing and subsurface material quality (final holes based on updated mine plan are under way);
• Geomechanical drilling to confirm rock strength, hardness and pit slope parameters (complete);
• PFS level metallurgical test work (ongoing);
• Flora and fauna studies (complete);
• Installation of a weather station (complete).

The Company has selected independent engineers Moose Mountain Technical Services and Knight Piesold Ltd. to prepare a PFS study. MMTS is an association of Geologists, Engineers and Technicians providing experienced knowledge in Geology, Mine Engineering, and Metallurgical Services and Support to the mining industry for over 15 years. Through their network of associates they provide an integrated team of experts and QP’s. Services range from early grassroots exploration and development, block model builds, resource and reserve estimates, advanced planning and studies for mine proposals (including operational support), process design and permitting process guidance and support. MMTS has experience working on coal, gold, silver, copper, molybdenum, and tungsten deposits throughout North and South America and around the world. A list of specific projects worked on by MMTS can be found at www.moosemmc.com.

KP is an international consulting firm and recognized leader in providing engineering and environmental services. KP’s expertise has been applied to hundreds of surface and underground mining projects in all stages of development and a broad range of environmental settings. KP provides industry leading services in water and waste management, tailings disposal, heap leach pads, rock mechanics and environmental services, and has been recognized for innovative services that meet high standards of reliability, security and cost effectiveness.

About the Ixtaca Drilling Program and the Ixtaca Zone
The Ixtaca Zone is a blind discovery made by the Company in 2010 on claims staked by the Company. The deposit is an epithermal gold-silver deposit, mostly hosted by veins in carbonate units and crosscutting dykes (“basement rocks”) with a minor component of disseminated mineralisation hosted in overlying volcanic rocks.

The Ixtaca deposit is located in a developed part of Mexico in Puebla State, the location of significant manufacturing investments including Volkswagen and Audi plants. The deposit is accessed by paved road and is roughly 20 kilometres from an industrial park with rail service where significant manufacturers such as Kimberly Clarke have facilities. Any potential mining operation at Ixtaca would be located in an area previously logged or cleared with negligible to no current land usage.

The Company has access to the entire project area and works closely with local officials and residents. The Company has employed roughly 70 people in its exploration program who live local to the Ixtaca deposit. For example, local employees have made up virtually all the drilling staff and have been trained on the job to operate the Company’s wholly owned drills. The Company has implemented a comprehensive science based and objective community relations and education program for employees and all local stakeholders to transparently explain the exploration and development program underway as well as the potential impacts and benefits of any possible future mining operation at Ixtaca. The Company regards the local inhabitants to be major stakeholders in the Ixtaca deposit’s future along with the Company’s shareholders. Every effort is being made to create an open and clear dialogue with our stakeholders to ensure that any possible development scenarios that could evolve from the anticipated PFS are properly understood and communicated throughout the course of the Company’s exploration and development program. To better explain the impacts of a mining operation at Ixtaca the Company has conducted numerous tours for local residents to third party operated mines in Mexico so that interested individuals can form their own opinions of mining based on first-hand experience. The Company invites all interested parties to visit www.almadenminerals.com to find out more about our community development, education and outreach programs.

Technical Details of the Ixtaca Drilling Program
The Main Ixtaca and Ixtaca North Zones of veining are interpreted to have a north-easterly trend. Holes to date suggest that the Main Ixtaca and Ixtaca North Zones are sub vertical with local variations. This interpretation suggests that true widths range from approximately 35% of intersected widths for a -70 degree hole to 94% of intersected widths for a -20 degree hole. The drilling completed to date has traced mineralisation over 1,000 meters along this northeast trend. The Chemalaco (Northeast Extension) Zone strikes roughly north-south (340 azimuth) and dips at 55 degrees to the west. This interpretation suggests that true widths range from approximately 82% of intersected widths for a -70 degree hole to 99% of intersected widths for a -40 degree hole. The orientation of the new vein zone intersected in the holes reported today is not well understood and true widths cannot be calculated at this time.

Mr. Norm Dircks, P.Geo., a qualified person (“QP”) under the meaning of NI 43-101, is the QP and project manager of Almaden’s Ixtaca program and reviewed the technical information in this news release. The analyses reported were carried out at ALS Chemex Laboratories of North Vancouver using industry standard analytical techniques. For gold, samples are first analysed by fire assay and atomic absorption spectroscopy (“AAS”). Samples that return values greater than 10 g/t gold using this technique are then re-analysed by fire assay but with a gravimetric finish. Silver is first analysed by Inductively Coupled Plasma – Atomic Emission Spectroscopy (“ICP-AES”). Samples that return values greater than 100 g/t silver by ICP-AES are then re analysed by HF-HNO₃-HCLO₄ digestion with HCL leach and ICP-AES finish. Of these samples those that return silver values greater than 1,500 g/t are further analysed by fire assay with a gravimetric finish. Intervals that returned assays below detection were assigned zero values.

Blanks, field duplicates and certified standards were inserted into the sample stream as part of Almaden’s quality assurance and control program which complies with National Instrument 43-101 requirements.

Cautionary Note concerning estimates of Measured, Indicated and Inferred Mineral Resources
This news release uses terms that comply with reporting standards in Canada and certain estimates are made in accordance with Canadian National Instrument 43-101 (“NI 43-101”). NI 43-101 is a rule developed by the Canadian Securities Administrators that establishes Canadian standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. These standards differ significantly from the requirements of the U.S. Securities and Exchange Commission (“SEC”), and mineral resource information contained herein may not be comparable to similar information disclosed by United States companies.

This news release uses the terms “measured mineral resources”, “indicated mineral resources” and “inferred mineral resources” to comply with reporting standards in Canada. We advise United States investors that while such terms are recognized and required by Canadian regulations, the SEC does not recognize them. United States investors are cautioned not to assume that any part or all of the mineral deposits in such categories will ever be converted into mineral reserves under SEC definitions. These terms have a great amount of uncertainty as to their existence, and great uncertainty as to their economic and legal feasibility. Therefore, United States investors are also cautioned not to assume that all or any part of the “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” exist. In accordance with Canadian rules, estimates of “inferred mineral resources” cannot form the basis of pre-feasibility or other economic studies. It cannot be assumed that all or any part of the “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” will ever be upgraded to a higher category.

Further holes have been drilled on the aforementioned section and results are pending. The mineralisation intersected in all holes is limestone hosted and located outside of the 2016 Amended PEA pit. Highlights from holes TU-16-318A and TU-16-462 include the following intercepts:

About Almaden
Almaden Minerals Ltd. is a well-financed company which owns 100% of the Tuligtic project in Puebla State, Mexico, subject to a 2.0% NSR royalty held by Almadex Minerals Limited. Tuligtic covers the Ixtaca Gold-Silver Deposit, which was discovered by Almaden in 2010.

On Behalf of the Board of Directors

“Morgan Poliquin”
Morgan J. Poliquin, Ph.D., P.Eng.
President, CEO and Director
Almaden Minerals Ltd.

Neither the Toronto Stock Exchange (TSX) nor the NYSE MKT have reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release which has been prepared by management. Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements, including but not limited to, those with respect to potential expansion of mineralization, potential size of mineralized zone, and size and timing of exploration and development programs, estimated project capital and other project costs and the timing of submission and receipt and availability of regulatory approvals involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of Almaden to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks related to international operations and joint ventures, the actual results of current exploration activities, conclusions of economic evaluations, uncertainty in the estimation of mineral resources, changes in project parameters as plans continue to be refined, environmental risks and hazards, increased infrastructure and/or operating costs, labour and employment matters, and government regulation and permitting requirements as well as those factors discussed in the section entitled “Risk Factors” in Almaden’s Annual Information form and Almaden’s latest Form 20-F on file with the United States Securities and Exchange Commission in Washington, D.C. Although Almaden has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Almaden disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required pursuant to applicable securities laws. Accordingly, readers should not place undue reliance on forward-looking statements.

$HWAY Names #RobertDries #CFO

NASHVILLE, Tenn., Aug. 10, 2016  — Healthways, Inc. (NASDAQ:HWAY) announced today that Robert E. Dries has been named executive vice president and chief financial officer, effective August 22, 2016. Dries will succeed Alfred Lumsdaine, who is expected to join Sharecare, Inc. in October 2016 in connection with the previously announced sale of Healthways’ total population health services business to Sharecare.

Dries joins Healthways after serving in a variety of executive financial roles throughout his 27-year career.  Most recently, he served as senior vice president, financial operations of Omnicare, Inc., a leading provider of pharmaceutical care for senior populations and a subsidiary of CVS Health Corporation. During his 20-year tenure at Omnicare, Dries held a variety of financial leadership roles. His responsibilities included corporate financial planning and analysis, forecasting and budgeting, as well as cross-functional oversight and support for sales, account management, purchasing, trade relations, and government affairs.

“As we recently announced, our strategic plan to drive growth and strong financial performance will center on our Network Solutions business – a leading provider of network development and management solutions in healthcare. Moving forward, we will focus on our existing three networks, SilverSneakers, Prime Fitness and Physical Medicine, with a heightened emphasis on targeted population health for the 50+ population,” said Donato Tramuto, chief executive officer of Healthways.

“After a thoughtful executive search process, we are excited to welcome Bob to our leadership team. His meaningful financial leadership experience in a public company, strong analytical, business and strategic mindset and deep understanding of our target consumer audience will be vital as we implement our strategy. In addition, we wish Alfred all the best in his transition to Sharecare.  We thank him for his years of service to Healthways, for serving as our interim CEO last year, and for his indispensable leadership in the recent sale of our total population health services business to Sharecare.  Alfred will stay with us to the end of September in an executive consulting capacity to assist Bob as he transitions into the CFO role,” Tramuto continued.

“It is an unprecedented time in healthcare, and Healthways is at the forefront of innovating targeted population health. This is also a historic moment in the company’s 30-year history, and I look forward to contributing to Healthways’ success in the future,” said Dries.

Dries, a graduate of the University of Kentucky and a certified public accountant, will be based in Franklin, Tennessee.

Media Contact: 
Cindy Wakefield
(615) 614-4862
Cindy.Wakefield@healthways.com

Investor Relations Contact:
Chip Wochomurka   
(615) 614-4493
chip.wochomurka@healthways.com

$CDXC Scientists Find Important Clue to Restoring Muscle Function #Aging

Published study in mice points to the potential of a form of vitamin B₃ referred to as NR to trigger this regenerative process

IRVINE, Calif., Aug. 10, 2016  — ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that University of Pennsylvania researchers have uncovered an important clue as to why our muscles weaken as we age, and how NR (nicotinamide riboside)– when combined with exercise and a healthy diet – might help us to maintain or even regain some of that muscle strength. The work was led by the group of Dr. Joseph Baur of the Penn’s Perelman School of Medicine, together with collaborators at Princeton University and Queens University, Belfast. In results of a recent mouse study published as the cover story of volume 24, issue 2 of Cell Metabolism, the researchers describe how NR helps to reactivate a protective metabolic process in muscle that tends to be lost as aging occurs.

Lead author David W. Frederick from the Perelman School of Medicine explains that the research team was interested in a molecule found naturally in the body called NAD+, which is responsible for unlocking the body’s ability to produce the energy necessary to fuel all its essential functions and processes such as metabolism and DNA repair. “We know that the amount of NAD+ in muscles declines as we age. But what was completely unknown before this study was whether that decline had any functional consequences.” The researchers concluded that the level of NAD+ in muscle cells is important to muscle function, and that it may be possible to restore muscle function lost due to aging by replenishing NAD+ levels.

To gain answers to their questions, the researchers used two groups of young, healthy mice in this study. In one group of mice – called the knockout mice – researchers reduced NAD+ levels in their muscles by knocking out a critical enzyme needed in the NAD+ production process, then measured their muscle strength and endurance on a treadmill. “The data showed that we can shrink NAD+ levels in the muscles down to about 15 percent of their normal range, and the muscles were still functional. But over time, that NAD+ loss led to progressive muscle weakness and lack of endurance on the treadmill test,” said Frederick.

Once loss of lean mass and endurance was apparent in the knockout mice, the NAD+ levels were then replenished by feeding water enriched with NR, an NAD+ precursor (or booster). After just one week, the knockout mice experienced a complete restoration of exercise capacity.

“What was surprising was that we didn’t need to replenish those NAD+ levels completely to see the muscle function begin to improve again. Just a small amount went a very long way toward restoring metabolic function. This study helped to identify the lower threshold of NAD+ tolerability, below which muscle function is lost.”

When commenting on some of the other surprising findings in the study, Ryan Dellinger, PhD, Director of Scientific Affairs at ChromaDex and one of the co-authors of the study shared that, “Importantly, in a head-to-head study, NR showed that it was more effective in restoring muscle function in this study than a more common form of vitamin B₃, nicotinamide. More results confirming this fact should be publishing soon.”

What these results could mean for the future
Frederick cautions that NR should not be construed as a performance enhancer as a result of these study findings. “Rather, we’re optimistic that future studies may show that supplementing with NR may help us to retain our muscle mass as we age. While this mouse study provides proof of the principle that NR can affect the NAD+ pool in muscles and that NAD+ can affect the consequences of aging, it is too early to know if this same biology will translate to humans.”  Frederick adds that there are many human muscle wasting diseases, such as Muscular Dystrophy, in which the NAD+ pool might be compromised. “Loss of NAD+ might be a feature that has previously been underappreciated in these diseases.”

ChromaDex CEO and co-founder, Frank Jaksch, Jr. agreed, “This research demonstrates the effectiveness of NR as an NAD+ precursor and the pivotal role it can play in muscle health and aging. One of the things that motivates us most at ChromaDex is the hope that the work that we and all our partners are doing will help people live healthier throughout their lives.  We are excited to see the next wave of research results from the active human clinical trials underway with additional collaborative partners which were announced last month.”

NIAGEN^® brand NR is an ingredient in a number of vitamin supplements available today.

About NAD+:
NAD+ is a metabolite that is essential for cellular metabolism and cellular energy production within the “powerhouses of the cell” – the mitochondria. The mitochondria’s key role within the cell is to convert nutrients such as fats, proteins and carbohydrates into energy which is necessary to power all bodily systems and functions. Decreased efficiency in the mitochondria is linked to of adverse health conditions such as metabolic syndrome.

About the NAD+ precursor (or booster), Nicotinamide Riboside (NR):
Sometimes referred to as “The forgotten B₃,” the benefits of NR remained unknown for years after its initial discovery and classification as a vitamin B_3, due to the lack of advanced understanding of nucleotide science. It was not until 2004 that this hidden gem resurfaced after Dr. Charles Brenner, then professor at Dartmouth, identified the missing link as to how NR becomes NAD+.  This discovery also suggested that NR also had the ability to boost NAD+ in a more energy efficient way than could be achieved with its B₃ cousins, niacin or nicotinamide, leaving the body extra energy to focus on its critical needs and processes.  NR’s unique energy sparing ability to produce NAD+ has excited the scientific community around the world.  This excitement has led to 70 material transfer agreements to top research institutions all studying the effects of NR in separate therapeutic endpoints. The body of evidence continues to build as researchers make seminal discoveries characterizing the unique properties of NR in a wide range of health benefits, including increased mitochondrial health resulting in improved cellular energy production, increased muscle endurance, neuroprotection, improvements in longevity, protection against weight gain when consuming a high fat diet, protection against oxidative stress and improvement of blood glucose and insulin sensitivity. For additional information about NR and studies using NIAGEN^®, visit www.ChromaDex.com.

About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN^® nicotinamide riboside; pTeroPure^® pterostilbene; PURENERGY^®, a caffeine-pTeroPure^® co-crystal; IMMULINA^™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the role of NR in maintaining or regaining muscle strength. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.  ChromaDex provided research materials as a collaborator for the study. ChromaDex’s Director Scientific Affairs, Ryan Dellinger, PhD, are named authors on the study.

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing 
949-537-4103
breaho@chromadex.com

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations 
949-419-0288
andrewj@chromadex.com

$GSV #GoldStandard Aug 10 #ConferenceCall

ANCOUVER, BRITISH COLUMBIA–(Aug. 10, 2016) – Gold Standard Ventures Corp. (TSX VENTURE:GSV) (NYSE MKT:GSV) (“Gold Standard” or the “Company”) announces that Gold Standard’s President and CEO, Jonathan Awde, and vice-president of exploration, Mac Jackson, will host a conference call and webcast with analysts and investors to review yesterday’s announced drill results, today at 11:00 AM Pacific time.

A live slide presentation will be available for viewing during the call from the link provided below.

Conference call

To participate in this conference call, please dial the following number approximately 10 minutes prior to the starting time:

Local / International: 416-640-5946

North American Toll- Free: 1-866-233-4585

Webcast

A webcast presentation will also be available for viewing in conjunction with the conference call. To access the webcast, please visit: http://momentumstreaming.com/index.php?id=120769

Callers can alternatively refer to the newly posted slides on Gold Standard’s website that will be referenced during the meeting.

For those unable to listen live, the webcast will remain available at the above link for one year following the call.

ABOUT GOLD STANDARD VENTURES – Gold Standard is an advanced stage gold exploration company focused on district scale discoveries on its Railroad-Pinion Gold Project, located within the prolific Carlin Trend. The 2014 Pinion and Dark Star gold deposit acquisitions offer Gold Standard a potential near-term development option and further consolidates the Company’s premier land package on the Carlin Trend. The Pinion deposit now has an NI43-101 resource estimate consisting of an Indicated Mineral Resource of 31.61 million tonnes grading 0.62 grams per tonne (g/t) gold (Au), totaling 630,300 ounces of gold and an Inferred Resource of 61.08 million tonnes grading 0.55 g/t Au, totaling 1,081,300 ounces of gold, using a cut-off grade of 0.14 g/t Au. The Dark Star deposit, 2.1 km to the east of Pinion, has a NI43-101 resource estimate consisting of an Inferred Resource of 23.11 million tonnes grading 0.51 g/t Au, totaling 375,000 ounces of gold, using a cut-off grade of 0.14 g/t Au (announced March 3, 2015). The 2014 and 2015 definition and expansion of these two shallow, oxide deposits demonstrates their growth potential.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the NYSE MKT accepts responsibility for the adequacy or accuracy of this news release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. All statements, other than statements of historical fact, included herein including, without limitation, statements about our proposed exploration programs and future potential results are forward looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Risk factors affecting the Company include, among others: the results from our exploration programs, global financial conditions and volatility of capital markets, uncertainty regarding the availability of additional capital, fluctuations in commodity prices; title matters; and the additional risks identified in our filings with Canadian securities regulators on SEDAR in Canada (available at www.sedar.com) and with the SEC on EDGAR (available at www.sec.gov/edgar.shtml). These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.

CAUTIONARY NOTE FOR U.S. INVESTORS REGARDING RESERVE AND RESOURCE ESTIMATES

All resource estimates reported by the Company were calculated in accordance with the Canadian National Instrument 43-101 and the Canadian Institute of Mining and Metallurgy Classification system. These standards differ significantly from the requirements of the U.S. Securities and Exchange Commission for descriptions of mineral properties in SEC Industry Guide 7 under Regulation S-K of the U. S. Securities Act of 1933. In particular, under U. S. standards, mineral resources may not be classified as a “reserve” unless the determination has been made that mineralization could be economically and legally produced or extracted at the time the reserve determination is made. Accordingly, information in this press release containing descriptions of the Company’s mineral properties may not be comparable to similar information made public by US public reporting companies.

On behalf of the Board of Directors of Gold Standard,

Jonathan Awde, President and Director

$SIEN #Sientra Provides Update on Long-Term #Breast #Implant Manufacturing Solution

Announces Services Agreement with Vesta

SANTA BARBARA, Calif., Aug. 09, 2016  — Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today provided an update on its progress towards establishing a long-term manufacturing solution for its breast implant products. Sientra has entered into a services agreement with Vesta, a Lubrizol LifeSciences company and a leading medical device contract manufacturer of silicone products and other medical devices.

Under terms of the agreement, Vesta is establishing manufacturing capacity for Sientra and is working with the Company to finalize a long-term supply arrangement for its PMA-approved breast implants. Sientra anticipates that all project milestones will be achieved for the Company to submit a PMA Supplement to the FDA during the first quarter of 2017.

Jeffrey M. Nugent, Chairman and Chief Executive Officer of Sientra, said, “Our relationship with Vesta is an important component of our comprehensive manufacturing plan. Vesta is an established manufacturer with proven capabilities in producing implantable silicone medical devices and components with a strong reputation for quality and safety. We have already made significant progress with Vesta and we are confident that this ongoing relationship will enable us to uphold our promise to board-certified plastic surgeons to maintain an uninterrupted supply of our breast implant products. We believe our arrangement with Vesta will provide us a best-in-class supply chain that we can scale moving forward to support our long-term growth objectives.”

Mr. Nugent continued, “We are also looking forward to the prospects of working with Lubrizol LifeSciences and Vesta in the future on additional aesthetics technologies and innovations that can help meet unmet needs for our surgeons and their patients.”

“Lubrizol LifeSciences/Vesta is excited about furthering its commitment to deliver the highest quality medical components and products with an innovative strategic partner like Sientra,” said Deb Langer, Vice President and General Manager Lubrizol LifeSciences. “Our experience in the implantable cosmetic market and our know-how of silicone component manufacturing positions us well to best support Sientra’s continued success.”

About Sientra

Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs.  The Company also offers a range of other aesthetic and specialty products including bioCorneum®, the professional choice in scar management.

About Vesta

Headquartered in Franklin, Wisconsin, Vesta Intermediate Funding, Inc. (“Vesta”) is a Lubrizol LifeSciences company.  Vesta has more than 40 years of experience serving the medical device industry, exclusively specializing in precision thermoplastic extrusion and comprehensive silicone fabrication. Vesta’s quality, competency and reliability have earned the company business relationships with hundreds of OEMs worldwide. For more information, please visit the company’s website at www.vestainc.com or contact Vesta at info@vestainc.com.

Forward- looking statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties.  Forward-looking statements include, but are not limited to, statements regarding the Company’s development of and progress towards a long-term manufacturing solution, the ability and timing of Vesta and the Company to complete the development and validation of a manufacturing facility in order for the Company to obtain FDA approval of its PMA Supplement,  the Company’s plan to provide an uninterrupted supply of its Breast Products, and the prospects of any future collaboration with Vesta or Lubrizol regarding additional aesthetic technologies.  Such statements are subject to risks and uncertainties, including the risks associated with contracting with any third-party manufacturer and supplier, as well as uncertainties that the development and validation of Vesta’s manufacturing facility will be timely completed, that a PMA Supplement or other regulatory requirements will be timely approved by the FDA or other applicable regulatory authorities, and that the Company and Vesta will successfully negotiate and enter into a definitive long-term supply arrangement.  Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s most recently filed Quarterly Report on Form 10-Q and and its Annual Report on Form 10-K for the year ended December 31, 2015 which Sientra filed with the Securities and Exchange Commission on March 10, 2016.  All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue,’’ ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify beliefs, estimates, projections and other forward-looking statements.  Forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any forward-looking statement.

Investor Contacts:
The Ruth Group
Nick Laudico / Zack Kubow
(646) 536-7030 / (646) 536-7020
IR@Sientra.com

$VIVE Announces #Regulatory #Approval for #Viveve System in #Singapore

Viveve System — Painless Out-Patient Procedure to Treat Vaginal Laxity — Now Approved for Marketing in 27 Countries Around the World

$EGRX Positive Outcome #FDA #NDA Meeting for #RYANODEX in #HeatStroke

Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) today announced that the U.S. Food and Drug Administration (“FDA”) has determined that no additional human safety and efficacy data is required for the submission of Eagle’s New Drug Application (“NDA”) for Ryanodex® for the treatment of exertional heat stroke (“EHS”), an investigational new indication for the product, further confirming that a hybrid development program comprised of clinical data from EHS patients and preclinical data from animal studies constitutes an adequate regulatory pathway for the NDA submission.

Eagle has also reduced its future Ryanodex royalty obligations to its licensing partner from 15% to 3% of net sales in exchange for $15 million in cash.

“We believe there is significant long-term value in our Ryanodex portfolio. Following our positive meeting with the FDA, we have an agreement for an NDA submission for EHS. We anticipate requesting priority review of the application and, if granted by the FDA, being the first to market with a potentially life-saving treatment for EHS as early as next year,” said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals. “Furthermore, we believe the continued growth of the currently approved Malignant Hyperthermia indication and our plans to expand the Ryanodex label to include the potential treatment of Ecstasy and Methamphetamine intoxication will allow us to maximize the value of this product. Therefore, we increased our commitment to the portfolio by investing a portion of our cash to purchase substantially all of the royalty obligation owed on Ryanodex. This will allow us to increase the earnings potential of Ryanodex, benefitting shareholders for many years to come,” he added.

“We are pleased that the FDA recognized that our study during the Hajj last September, in combination with results from our ongoing animal studies, will provide adequate safety and efficacy data to complete our NDA submission. And, we are very grateful to the authorities of Saudi Arabia for their assistance in supporting the human study. We expect to complete our NDA filing upon successful conclusion of our animal work,” added Adrian Hepner, Executive Vice President and Chief Medical Officer.

The animal studies to support the NDA are currently underway. Upon successful completion of the animal studies, Eagle anticipates requesting priority review for its NDA submission. If approved, EHS would be the second indication for Ryanodex which is currently approved for the treatment of malignant hyperthermia (“MH”) and for the prevention of MH in patients at high risk.

Eagle’s Ryanodex for the treatment of EHS has previously been granted fast track designation and orphan drug designation by the FDA. Eagle is evaluating its option to submit a rolling NDA, as allowed by the fast track designation, which permits completed sections of an NDA to be submitted on an ongoing basis. Ryanodex is protected by two filed and five issued patents.

EHS is the most severe form of heat-related illness, characterized by core body temperature of 104° F (40° C) or greater and significant neurological dysfunction. It carries high rates of morbidity and mortality. The central nervous system is very sensitive to hyperthermia, which may lead to severe neurologic complications and permanent brain damage. EHS is a leading cause of death in young athletes and non-combat related fatalities in the military.

In September 2015, Eagle completed its clinical study in EHS patients during the Hajj pilgrimage in Saudi Arabia. The study was conducted at the Emergency Departments of four hospitals in the Makkah region of Saudi Arabia. Due to the life-threatening, unpredictable and sudden nature of EHS, it was necessary to conduct the study in a ‘real world’ emergency and acute-care medical setting.

Study results demonstrated that the use of Ryanodex with the current standard of care (“SOC”) showed substantial evidence of increased effectiveness in treating EHS than SOC alone, and that the safety profile of Ryanodex in EHS patients was consistent with the known and well characterized safety profile of Ryanodex for the currently approved indications. The current SOC for the treatment of EHS is limited to body cooling by physical methods (e.g., water immersion, evaporative cooling).

Additional information regarding the human clinical study and its outcomes can be found in Eagle’s press release dated December 17, 2015.

About Exertional Heat Stroke

EHS is a rare, sudden and unpredictable disorder that constitutes a medical emergency which may result in severe multi-organ dysfunction and death. EHS is more commonly seen in young people undergoing exertional physical activity in a hot weather environment, and is one of the leading causes of death in young athletes. EHS cases are also observed in construction workers, firefighters, military personnel, and farmers. There is no currently approved drug product for the treatment of EHS.

About Ryanodex

Ryanodex (dantrolene sodium) for injectable suspension is indicated for the treatment of malignant hyperthermia (“MH”) in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.

In February 2015, Ryanodex was granted seven years of U.S. market exclusivity for the treatment of MH by the U.S. Food and Drug Administration (“FDA”).

Important Safety Information

Ryanodex is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia, including:

Discontinuing triggering anesthetic agents
Increasing oxygen
Managing the metabolic acidosis
Instituting cooling when necessary
Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in Ryanodex is insufficient to maintain diuresis).
Precautions should be taken when administering Ryanodex preoperatively for the prevention of malignant hyperthermia, including monitoring vital signs, avoiding known triggering agents, and monitoring for early clinical and metabolic signs of malignant hyperthermia that may indicate additional treatment is needed.

The administration of dantrolene sodium is associated with loss of grip strength and weakness in the legs, as well as drowsiness, dizziness, dysphagia, dyspnea, and decreased inspiratory capacity. Patients should not be permitted to ambulate without assistance until they have normal strength and balance. Care must be taken to prevent extravasation of Ryanodex into the surrounding tissue due to the high pH of the reconstituted Ryanodex suspension and potential for tissue necrosis.

Ryanodex full Prescribing Information can be found at www.RYANODEX.com.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA’s 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words and phrases such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potential,” “entitles,” “optimistic” “could” “look forward” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events, including: the earnings potential and long-term value of Ryanodex; the safety and efficacy of Ryanodex for the treatment of EHS; the satisfactory completion of studies to support the indication of Ryanodex for treatment of EHS; FDA approval of the use of Ryanodex for the treatment of EHS; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to: whether Eagle will generate earnings and realize long-term value from Ryanodex; whether the FDA will ultimately approve Ryanodex for the treatment of EHS; whether our studies will support the safety and efficacy of Ryanodex for the treatment of EHS; and other risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Investor Relations for Eagle Pharmaceuticals, Inc.
In-Site Communications
Lisa M. Wilson, 212-452-2793
President

$IMI to Present at 2016 #FlashMemorySummit on 3D Cross-Point #NonVolatile #Memory

SAN JOSE, Calif., Aug. 9, 2016  — Intermolecular, Inc. (NASDAQ: IMI), the trusted partner in materials innovation, today announced it will present at the Flash Memory Summit on Thursday, August 11, 2016, at 8.30 am during the session 301-C: Intel-Micron 3D Xpoint^TM: The Next Generation Non-Volatile Memory (New Technologies Track).

Milind Weiling, Vice President for Electronic Applications at Intermolecular, will cover the challenges in vertically stackable selectors for 3D Cross-Point Non Volatile Memories and propose a development methodology using high-throughput physical vapor deposition (PVD) and test-based experimentation to identify the most promising selector characteristics and potential material systems.

In addition, Intermolecular will chair an open roundtable session where participants can discuss developments in RRAM during the Expert at the Table Session on Tuesday, August 9, from 7:00 p.m. to 8:30 p.m. PDT.

About Intermolecular, Inc.

Intermolecular® is the trusted partner for advanced materials innovation. Advanced materials are at the core of innovation in the 21^st century for a wide range of industries including semiconductors, consumer electronics, automotive and aerospace. With its substantial materials expertise; accelerated learning and experimentation platform; and information and analytics infrastructure, Intermolecular has a ten-year track record helping leading companies accelerate and de-risk materials innovation.

“Intermolecular” and the Intermolecular logo are registered trademarks; all rights reserved. Learn more at www.intermolecular.com or follow on Twitter at @IMIMaterials.